Figure 3From: Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanomaOveral survival univariate analyses of the effect of Fotemustine (FM, left panel) and Interferon-α2b (IFN, right panel) within subgroups of patients. The area of each square is proportional to the size of the subgroup; horizontal lines depict 95% confidence intervals of the hazard ratio estimates.Back to article page